Avalo Therapeutics, Inc. (AVTX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Avalo Therapeutics, Inc. — ARS Filing
# 🧾 What This Document Is This is Avalo Therapeutics' **Annual Report to Shareholders (ARS)** for 2025. Think of it as the company's official, detailed year-in-review summary sent to its owners (the shareholders). It combines the comprehensive business and financial reporting of a formal 10-K fili
Avalo Therapeutics, Inc. — DEF 14A Filing
# 📄 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Avalo Therapeutics. Think of it as an invitation and information packet for the company's big annual shareholder meeting. It explains what will be voted on, who is running the company, and how much the leaders get paid
SEC filings
All filings →Insider trades
All insider trades →Avalo Therapeutics, Inc. has no reported insider trades in the last 90 days.